ShRNA-mediated silencing of PD-1 augments the efficacy of chimeric antigen receptor T cells on subcutaneous prostate and leukemia xenograft

Chimeric antigen receptor T cells (CAR-T) immunotherapy has shown promising clinical results in the treatment of leukemia and lymphoma, but the effectiveness is limited for solid tumors. The PD-1/PD-L1 pathway is a key immunosuppressive mechanism for cancer cells to avoid eradication by CAR-T cells....

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Biomedicine & pharmacotherapy 2021-05, Vol.137, p.111339-111339, Article 111339
Hauptverfasser:	Zhou, Jing-e, Yu, Jing, Wang, Yeying, Wang, Hao, Wang, Jing, Wang, Yiting, Yu, Lei, Yan, Zhiqiang
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antigens, CD19 - metabolism Cell Line, Tumor Gene Silencing - immunology Heterografts - drug effects Humans Immunotherapy Immunotherapy, Adoptive - methods Leukemia - drug therapy Leukemia - immunology Male Mice Mice, Inbred NOD Mice, SCID PD-1 silenced CAR-T cells PD-1/PD-L1 Programmed Cell Death 1 Receptor - antagonists & inhibitors Programmed Cell Death 1 Receptor - genetics Prostatic Neoplasms - drug therapy Prostatic Neoplasms - immunology Receptors, Chimeric Antigen - immunology RNA, Small Interfering - pharmacology ShRNA Subcutaneous xenograft T-Lymphocytes - immunology Xenograft Model Antitumor Assays
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!